Every five to ten years, a therapy or group of therapies emerge from company pipelines, providing particular challenges for Australia's policymakers. They are almost always reimbursed, but it generally takes time and is often accompanied by wider changes.
These system-shifting therapies come along every few years, but this is different
April 29, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News

